| Popis: |
The recent discovery of the dihydropyridine derivatives Bay k 8644 [55, 56, 62] YC-170 [61] and CGP 28392 [14, 68] together with the well-known nifedipine-like drugs have provided an avenue for a classification of dihydropyridines (DHPs) into two separate groups (Table 1). The members of the first group are termed “Ca2+ antagonists” or “Ca2+ channel inhibitors.” These drugs inhibit voltage-dependent Ca2+ influx both in smooth and cardiac muscle. This results in vasodilation in the former and negative inotropy in the latter [38, 58]. The second group of compounds activate Ca2+ channels, producing vasoconstriction and positive inotropy, i. e., effects which are opposite to those produced by the “Ca2+ antagonists” [55, 56, 61-63, 68]. These drugs have been termed “Ca2+ agonists” or “Ca2+ channel activators” [35, 55, 56, 65]. |
